VC-backed PepStar Sells Inflammation Peptide Drug Programme to Gilead
27 Oct 2026
US$ 20.00
PepStar Therapeutics Ltd (PepStar), backed by Lilly Asia Ventures, HongShan Capital Group, F-Prime Capital and...
Related Publications
Listen to Australia/New Zealand Investments (Subscribers' Weekly 30 Oct 2026)...
Subscribers’ Weekly for the week ending 30th Oct 2026...
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.